Critical Limb Ischemia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The critical limb ischemia treatment market size was valued at USD 5.19 billion in 2025 and is estimated to grow from USD 5.47 billion in 2026 to reach USD 7.03 billion by 2031, at a CAGR of 5.15% during the forecast period (2026-2031). This report is Segmented by Treatment Type (Devices, Drugs, Regenerative & Cell-Based Therapies), End-User (Hospitals, Ambulatory Surgical Centers, Specialty Vascular & Wound-Care Clinics), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Critical Limb Ischemia Treatment Market Trends and Insights

Rising Diabetes and PAD Prevalence

The International Diabetes Federation estimated 537 million adults living with diabetes in 2024 and forecasts 643 million by 2030, with four-fifths of new cases clustered in developing regions. Peripheral artery disease complicates 12%-15% of older diabetics, and the Centers for Disease Control and Prevention confirmed a 15-fold higher amputation risk for diabetic patients compared with non-diabetics. In India, undiagnosed PAD prevalence exceeds 25% among urban diabetics because primary care rarely performs ankle-brachial index testing, but new public screening mandates will soon expose this hidden cohort. China faces a similar surge, reporting 140 million diabetics in 2025, yet fewer than 30% receive statins, fueling progression to critical limb ischemia. These data point to a durable demand driver for revascularization devices, adjunct pharmacotherapy, and ultimately regenerative therapeutics.

Growing Adoption of Minimally Invasive Revascularization Devices

Percutaneous transluminal angioplasty and stenting represented 78% of all U.S. critical limb ischemia interventions in 2025, up from 62% five years earlier, due to shorter recovery times and lower hospital costs. Boston Scientific’s paclitaxel-free Ranger balloon achieved an 82% 12-month primary patency rate in below-the-knee lesions, capturing market share from legacy paclitaxel products. Medtronic’s IN.PACT Admiral balloon remains the leader in above-the-knee disease, with 2025 sales of USD 680 million; however, the company is diversifying into sirolimus coatings to navigate safety scrutiny. Segment diversification and rapid product cycles are therefore sustaining the device franchise even as novel biologics rise.

High Cost and Limited Reimbursement in Emerging Economies

Drug-eluting balloons and stents cost USD 1,800-3,200 in India, but government schemes reimburse just USD 600, forcing patients to pay more than a year's median income out of pocket. Brazil offers coverage in public hospitals, yet waiting times average 180 days, prompting wealthier patients to seek private centers at BRL 45,000 (approximately USD 9,000) per case. Gulf Cooperation Council nations cover CLI fully for their citizens, but expatriate coverage caps at USD 5,000 per year, which is well below real-world costs. Tiered product portfolios and local manufacturing are emerging as mitigation strategies.

Other drivers and restraints analyzed in the detailed report include:

• Aging Population Intensifying CLI Incidence
• FDA Breakthrough Designations Speeding BTK Device and Cell-Therapy Launches
• Underdiagnosis and Late Presentation

Segment Analysis

Devices accounted for 62.81% of 2025 revenue, anchored by drug-eluting stents, plain balloons, and atherectomy systems. Embolic protection devices accounted for just 3% of device revenue, as they are primarily reserved for high-risk distal work. Peripheral dilatation systems, such as Cardiovascular Systems’ Diamondback 360, grew 14% year-over-year, displacing plain angioplasty in calcified lesions. The growth of vascular and drug-eluting stents softened to a 3.2% CAGR amid headwinds from paclitaxel. Regenerative and cell-based therapies held an 8% share in 2025, but their 10.06% CAGR positions them to erode repeat device revenue, as successful biologic repair lowers re-intervention rates.

Complete Report Scope:

• By Treatment Type
  • Devices
    • Embolic Protection Devices
    • Peripheral Dilatation Systems
    • Balloon Dilators
    • Vascular & Drug-Eluting Stents
  • Drugs
    • Antiplatelet Agents
    • Antihypertensive Agents
    • Lipid-Lowering Agents
    • Antithrombotic Agents
  • Regenerative & Cell-Based Therapies
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Vascular & Wound-Care Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America dominated with a 44.32% share in 2025, due to U.S. Medicare’s generous reimbursement, which underpins device usage. However, scrutiny of paclitaxel and a mature installed base temper the acceleration. Canada reimburses CLI at CAD 8,500 (USD 6,300), which is 25% below U.S. rates, thereby restraining premium adoption. Mexico expanded its vascular capacity by 18% between 2023 and 2025; however, specialist scarcity continues to keep guideline adherence below 40%. U.S. limb-preservation protocols delivered via telehealth are opening adjacent Latin markets to American devices, further consolidating supplier advantage.

Germany halted broad paclitaxel reimbursement in 2024, resulting in a one-third reduction in national sales. Conversely, the United Kingdom issued positive guidance for LimFlow’s deep vein arterialization system in 2026, creating a GBP 45 million (USD 57 million) opportunity.

Asia-Pacific is the growth driver with an 11.53% CAGR. China’s approval of 14 home-grown drug-eluting devices between 2024 and 2025 reduced local prices by 60%, unlocking rural demand and expanding the critical limb ischemia treatment market size in the region. Japan grows 5.2% as reimbursement for cell therapies rose 18% in 2025. Australia’s TGA green-lit Cynata’s Cymerus therapy for compassionate use in 2025, reinforcing its role as a regenerative test bed.

Saudi Arabia has earmarked SAR 12 billion (approximately USD 3.2 billion) for 50 limb-preservation clinics by 2028. The UAE’s 2024 fast-track pathway shrank device approval times from 18 to 6 months, encouraging multinational launches. Sub-Saharan Africa remains underserved, with only 22% of patients in South Africa receiving revascularization due to cost and capacity constraints.

List of Companies Covered in this Report:

• Abbott Laboratories
• AngioDynamics
• B. Braun
• Biotronik SE & Co.
• Boston Scientific
• Cardiovascular Systems
• Cesca Therapeutics (ThermoGenesis)
• Cook Group
• Cynata Therapeutics
• Eli Lilly and Company
• LimFlow
• Medtronic
• Micro Medical Solutions
• Koninklijke Philips
• Pluristem Therapeutics
• Rexgenero
• Smiths Group
• Teva Pharmaceutical Industries
• Terumo Corp.
• W. L. Gore & Associates

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support